Our website content is currently being
updated to reflect our recent transactions.
Next Generation
Targeted & Personalized
Cancer Therapeutics

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a publicly-traded, clinical-stage biopharmaceutical company focused primarily on the acquisition, discovery, development and commercialization of proprietary therapeutics.

Frost Sullivan Award
Read the Frost & Sullivan Report »

From the CEO

Welcome to Sorrento Therapeutics! Our team is developing targeted and personalized therapeutics against cancer and other debilitating diseases. Sorrento’s goal is to deliver new innovative treatment options with high efficacy and safety to patients throughout the world. By working closely with scientists, doctors, patient organizations and other health care specialists, we are committed to improving the lives of patients and assist their caregivers in the fight against cancer, inflammatory and autoimmune diseases as well as other unmet medical needs.

Dr. Henry Ji
Director, President and CEO